HomeCompareASPZ vs ABBV

ASPZ vs ABBV: Dividend Comparison 2026

ASPZ yields 5633.80% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASPZ wins by $198694764127637.44M in total portfolio value
10 years
ASPZ
ASPZ
● Live price
5633.80%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$198694764127637.53M
Annual income
$191,991,025,658,507,530,000.00
Full ASPZ calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ASPZ vs ABBV

📍 ASPZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASPZABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASPZ + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASPZ pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASPZ
Annual income on $10K today (after 15% tax)
$478,873.24/yr
After 10yr DRIP, annual income (after tax)
$163,192,371,809,731,380,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ASPZ beats the other by $163,192,371,809,731,350,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASPZ + ABBV for your $10,000?

ASPZ: 50%ABBV: 50%
100% ABBV50/50100% ASPZ
Portfolio after 10yr
$99347382063818.81M
Annual income
$95,995,512,829,253,780,000.00/yr
Blended yield
96.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ASPZ
No analyst data
Altman Z
1047.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASPZ buys
0
ABBV buys
0
No recent congressional trades found for ASPZ or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASPZABBV
Forward yield5633.80%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$198694764127637.53M$102.3K
Annual income after 10y$191,991,025,658,507,530,000.00$24,771.77
Total dividends collected$198242881520921.88M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASPZ vs ABBV ($10,000, DRIP)

YearASPZ PortfolioASPZ Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$574,080$563,380.28$11,550$430.00+$562.5KASPZ
2$30,840,949$30,226,683.25$13,472$627.96+$30.83MASPZ
3$1,550,615,557$1,517,615,741.32$15,906$926.08+$1550.60MASPZ
4$72,969,817,068$71,310,658,421.86$19,071$1,382.55+$72969.80MASPZ
5$3,214,321,313,557$3,136,243,609,294.54$23,302$2,095.81+$3214321.29MASPZ
6$132,552,939,184,997$129,113,615,379,490.69$29,150$3,237.93+$132552939.16MASPZ
7$5,117,922,927,741,785$4,976,091,282,813,839.00$37,536$5,121.41+$5117922927.70MASPZ
8$185,035,906,109,383,800$179,559,728,576,700,100.00$50,079$8,338.38+$185035906109.33MASPZ
9$6,265,176,139,373,827,000$6,067,187,719,836,787,000.00$69,753$14,065.80+$6265176139373.76MASPZ
10$198,694,764,127,637,540,000$191,991,025,658,507,530,000.00$102,337$24,771.77+$198694764127637.44MASPZ

ASPZ vs ABBV: Complete Analysis 2026

ASPZStock

Asia Properties, Inc. does not have any significant operations. It intends to acquire gold claims and mines in Nevada and Alaska; and securitizing them on the blockchain via initial coin offering and security token offering process. The company was incorporated in 1998 and is based in Cheyenne, Wyoming.

Full ASPZ Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ASPZ vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASPZ vs SCHDASPZ vs JEPIASPZ vs OASPZ vs KOASPZ vs MAINASPZ vs JNJASPZ vs MRKASPZ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.